Projektbeschreibung
Behandlung der arteriellen Hypertonie
Hoher Blutdruck bzw. Hypertonie ist eine Erkrankung, welche die Arterien des Körpers in Mitleidenschaft zieht und das Risiko für Herzerkrankungen erhöht. Die zugrundeliegende Ursache des Bluthochdrucks zu verstehen sowie die endokrine Hypertension festzustellen, sind für die Therapie von zentraler Bedeutung. Das EU-finanzierte Projekt HT-ADVANCE verfolgt das Ziel, in klinischen Studien Mehrkomponenten-Biomarker zu validieren, die zur Stratifizierung und Verbesserung der Behandlung von Personen mit Bluthochdruck beitragen können. Die Biomarker umfassen genetische, genomische und metabolomische Merkmale, die sich auf die Ausprägung des Bluthochdrucks beziehen. Langfristig ist zu erwarten, dass mit der Einführung dieser Biomarker in die klinische Routinepraxis kardiometabolische Komplikationen verringert und die Behandlung des Bluthochdrucks verbessert werden.
Ziel
In HT-ADVANCE we aim to revolutionise personalised management of arterial hypertension (HT) by using multi-omics (MOMICS) stratification biomarkers as companion diagnostics for the prescription of existing drugs.
HT is the most important global risk factor for death and morbidity but is uncontrolled in more than 50% of patients. Causes of treatment failure include lack of identification of secondary forms such as endocrine hypertension (EHT) which can be curable by specific therapy. In addition, there is variable response to individual drugs and trial-and-error treatment leads to poor HT control and frustration for both patients and clinicians.
The objective of HT-ADVANCE is to validate two multicomponent stratification biomarkers in patients with HT in order to i) identify patients with EHT, and ii) predict response to treatment in patients with primary hypertension. The hypothesis is that MOMICS biomarkers reflect specific forms of hypertension and susceptibility to specific drugs.
To this end, we will run three clinical trials (HT-ENDO, HT-TREAT and HT-PREDICT) and apply machine learning techniques to integrate the genetic, genomic and metabolomic features that constitute the MOMICS biomarkers in order to generate accurate diagnostic and therapeutic response predictions for clinicians. We will also perform economic evaluation of the use of MOMICS for the treatment of HT, produce ethical and legal recommendations for clinical decision making, and develop a plan for their implementation as companion diagnostics.
The study will be conducted by several HT Centres of Excellence and will build on the success of the ENSAT-HT project that has established methods and pipelines for integrating datasets derived from multiple platforms.
We expect that HT-ADVANCE will provide a step change in the management of HT by enabling a personalised, more efficient and cost-effective treatment strategy, and importantly, will prevent the ensuing cardio-metabolic complications.
Wissenschaftliches Gebiet
Schlüsselbegriffe
Programm/Programme
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenFinanzierungsplan
HORIZON-RIA - HORIZON Research and Innovation ActionsKoordinator
75654 Paris
Frankreich